PATENT CLAIM ANALYSIS

Application Number: 16075224
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "003800"]

Abstract:
The present invention relates to methods and pharmaceutical compositions for the treatment of viral infection.

Claim (Index 3):
The method according to  claim 2  wherein said AAC-11 inhibitor compound is a fusion protein comprising the polypeptide fused to at least one heterologous polypeptide.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15119274', '13817393', '12532064', '14713477', '11927400']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7394557680293925
- 35 USC 102 Novelty (BERT): 0.5260124669572822
- Combined Prediction Score: 0.7181114379221815
- Mean Citation Score: 286.5840560000001
- Max Citation Score: 312.78238
- Similarity Product: 214.4479382137632

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test